

# Emerging immuno-oncology options in metastatic NSCLC and SCLC: Clinical evidence and future perspectives



**MONDAY 20 SEPTEMBER 2021**  
**10:30–12:00 (CEST) CHANNEL 5**

## AGENDA & FACULTY

Introduction: Dual PD-L1 and CTLA-4 blockade in lung cancer  
**Dr Melissa Johnson (Chair)**

Emerging evidence for CTLA-4 inhibition in metastatic NSCLC  
**Dr Sanjay Popat**

Case study: Considerations for new combinations in metastatic NSCLC  
**Dr Niels Reinmuth**

PD-L1 +/- CTLA-4 blockade in SCLC: clinical evidence and future perspectives  
**Dr Taofeek Owonikoko**

Closing remarks: Future perspectives on combined immune blockade in lung cancer  
**Dr Melissa Johnson (Chair)**

Live Q&A session  
**All**



**Melissa Johnson (Chair)**  
Sarah Cannon Research Institute, Nashville, TN, USA



**Sanjay Popat**  
The Royal Marsden, London, UK



**Niels Reinmuth**  
Asklepios Lung Clinic, Munich, Germany



**Taofeek Owonikoko**  
University of Pittsburgh Medical Center, PA, USA

## AstraZeneca's Commitment to Sustainability



**\$15.5 million** invested in environmental efficiency projects in 2019 (NRRGG fund)



**CPD A Lists**  
One of three companies worldwide to achieve double A listing for Climate Change and Water Security for four consecutive years



**62% of our power** is sourced or generated from renewable sources



**100% of API** (Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



**18% reduction** in our water use since 2015



**25% of our vehicles** in Europe, North America or Japan are hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.